The firm is offering 3 million common shares at a price of $4 per share as well as an equal number of warrants at an exercise price of $5.00 per share.
Cancer Genetics said the deal is expected to provide it between $10 million and $12 million in revenues.
As part of the deal, expected to close on Oct. 9, Cancer Genetics will pay $14 million in cash and stock.
The deal continues the Cancer Genetics' reimbursement strategy and will provide 7.3 million people in Illinois with access to its cancer diagnostic services.
The firm's biopharma service business posted $2.7 million in revenues, while clinical service revenues grew to $1.3 million in the quarter.
Cancer Genetics' stalking horse bid is subject to higher bids from competitors, and the highest bid will require court approval.
The company also said that its cash burn rate for Q2 is estimated to be about $4.8 million, or $1.3 million more than its average cash burn.
The deal makes Cancer Genetics' diagnostic testing services available to more than one million people in Harvard Pilgrim's provider network.
The partners will provide complex oncology genomic testing, core central laboratory analysis, project and data management, and sample logistics.
The company's stock failed to meet the exchange's $1 minimum bid requirement.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.